

Krzewicka-Romaniuk Ewa, Siedlecka Dagna, Warpas Anna, Wójcicka Grażyna. Paraoxonase 1 as an important antiatherogenic agent. *Journal of Education, Health and Sport*. 2019;9(1):133-143. eISSN 2391-8306. DOI <http://dx.doi.org/10.5281/zenodo.2542320>  
<http://ojs.ukw.edu.pl/index.php/johs/article/view/6476>

The journal has had 7 points in Ministry of Science and Higher Education parametric evaluation. Part B item 1223 (26/01/2017).  
1223 Journal of Education, Health and Sport eISSN 2391-8306 7

© The Authors 2019;

This article is published with open access at Licensee Open Journal Systems of Kazimierz Wielki University in Bydgoszcz, Poland  
Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium,  
provided the original author (s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non commercial license Share alike.  
(<http://creativecommons.org/licenses/by-nc-sa/4.0/>) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited.

The authors declare that there is no conflict of interests regarding the publication of this paper.

Received: 03.01.2019. Revised: 11.01.2019. Accepted: 17.01.2019.

## PARAOXONASE 1 AS AN IMPORTANT ANTIATHEROGENIC AGENT

Ewa Krzewicka-Romaniuk<sup>1</sup>, Dagna Siedlecka<sup>1</sup>, Anna Warpas<sup>1</sup>, Grażyna Wójcicka<sup>1</sup>

<sup>1</sup>Department of Pathophysiology, Medical University of Lublin

**ABSTRACT:** The inverse relationship between High Density Lipoproteins (HDL) level and risk of ischaemic heart disease was proved by many epidemiological studies. Although the main mechanism of antiatherogenic activity of HDL is a reverse transport of cholesterol from peripheral tissues to the liver, HDL additionally carries some antioxidative enzymes like Paraoxonase 1 (PON1) which protects LDL and HDL lipoproteins from oxidative modification. A lot of antiatherogenic activities of HDL depends on PON1 activity.

**KEY WORDS:** PARAOXONASE, PON1, LIPOPROTEINS, HDL, ANTIATHEROGENIC

**INTRODUCTION:** The inverse relationship between High Density Lipoproteins (HDL) level and risk of ischaemic heart disease was proved by many epidemiological studies. In Framingham Heart Study low HDL level (<35mg/dl) was the strongest lipid ischaemic heart disease risk factor, even stronger than increase of Low Density Lipoproteins (LDL) or total cholesterol level or high triglycerides level (1). The main mechanism of antiatherogenic activity of HDL is a reverse transport of cholesterol from peripheral tissues to the liver, where cholesterol is excreted together with bile. However HDL is proved to act also as anti-inflammatory and antithrombotic agent. HDL particles additionally carry some antioxidative enzymes as Paraoxonase 1 (PON1), Paraoxonase 3 (PON3) or Platelet-activating factor acetylhydrolase (PAF-AH), which protect LDL and HDL lipoproteins from oxidative modification. A lot of antiatherogenic activities of HDL depends on PON1 activity(2).

## **BIOCHEMISTRY & MECHANISM OF ACTION**

PON1 is a glycoprotein of 354 amino acids and approximate molecular mass of 43 KDa. It is the member of a multigene family also containing *PON2* and *PON3*, the genes for which are located adjacent to each other on chromosome 7. The gene for PON1 is located between q21.3 and q22.1 on the long arm of chromosome 7 in humans (chromosome 6 in mice)(3). PON1 is an enzyme, for which main substrates appear to be lactones. PON1 presents also activity of arylesterase and can hydrolyse aromatic esters. However the active site of PON1 enzyme seems to be more specific for lactones than for aromatic esters or organophosphorus compounds (4). Therefore PON1 ability to hydrolyse lactones is its primary enzymatic activity, while arylesterase activity as well as paraoxonase activity are additional enzymatic features (5). All paraoxonases – PON1, PON2, PON3 have ability to act as lactonase or arylesterase, however arylesterase activity of PON 2 and PON 3 is very low. On the other site ability to hydrolyse organophosphorus compounds is characteristic only for PON1(6). Several studies of organophosphorus compounds exposed agricultural workers have indicated that individuals with PON1 genotypes associated with low activity (Q/M) had a greater frequency of various indices of organophosphorus compounds toxicity (chronic toxicity, genotoxicity, impaired thyroid function)(7–9). Hydrolytic activity of PON1 in relation to phospho-organic compounds and aromatic esters is dependent on the presence of calcium ions. However, the removal of calcium ions by chelating compounds (EDTA) does not cause loss of PON1 antioxidative capacity(10). PON1 presents also activity of tiolactonase and is able to hydrolyse proatherogenic homocysteine thiolactone(11,12). All three paraoxonases - PON1, PON2, PON3,- protect plasma lipoproteins and cell membranes from oxidative modification(13), by reduction of lipid hydroperoxides(14). What is interesting, PON1 and PON3 are predominantly located in the plasma associated with HDL while PON2 is not found in the plasma but has a wide cellular distribution(13).

PON1 paraoxonase, esterase and lactonase activity depends on the same site of the active enzyme, however different amino acid residues are responsible for the hydrolysis of different substrates(15). Histidine residues His115 and His 134 are responsible for the lactonase and aryl-esterase activity of the enzyme, whereas phenylalanine in position 222 (Phe222) is essential for paraoxonase activity(16,17). Peroxidase activity of the enzyme depends on a different active site and is conditioned by the presence of a cysteine residue at position 283(18).

PON1, synthesized in the liver, is secreted to the circulation, where it binds to the HDL lipoproteins containing apoA-I and apoJ(19). Probably scavenger receptor class B type 1 (SRB1) identified as receptors for HDL, are involved in this process(20). In vitro studies have proven that HDL molecules are not only the main acceptor, but also a potent stimulator of hepatocyte secretion of PON1(21). ApoA-I and phospholipids are necessary for stabilizing the activity of the secreted enzyme(21,22). In addition to HDL, small amounts of PON1 are also transported in postprandial chylomicrons and with the VLDL fraction(13). PON1 is not found in the LDL lipoprotein fraction.

## **ANTI-ATHEROGENIC ACTIVITY**

Low PON1 activity is observed in conditions conducive to atherosclerosis, such as hypercholesterolemia, diabetes(23,24), obesity(25) and insulin resistance(26). It has been proven that there is an inverse relationship between PON1 activity in plasma and the risk of developing cardiovascular diseases(27). Low PON1 concentration predicts also cardiovascular mortality in haemodialysis patients(28).

PON1 protects LDL and HDL lipoproteins from oxidative modification induced by reactive oxygen species, that are generated during oxidative stress(29). Oxidative modification of LDL accumulated in vessel wall plays significant role in initiation and progression of atherogenesis. Polyunsaturated fatty acids that are part of phospholipids in LDL molecules, undergo oxidation resulting in development of peroxides of these compounds that are capable of oxidizing further fatty acid molecules. Oxidized polyunsaturated acids eventually disintegrate into small fragments, so-called advanced products of lipid peroxidation, e.g. malondialdehyde (MDA) or 4-hydroxynonenal (4-HNE), which bind to ApoB and make it recognizable by macrophage receptors. This leads to uncontrollable, excessive cholesterol uptake by macrophages in the vascular wall and foam cell formation(30).

Under conditions of oxidative stress that takes place in the atherosclerotic vascular wall, HDL lipoprotein also undergoes oxidation(31). In the HDL molecule, both lipid and protein components are oxidatively modified(31). The result of HDL oxidation is the accumulation of lipid peroxidation products and the change in the physico-chemical properties of HDL particles and, consequently, the formation of so-called dysfunctional HDL, characterized by reduced ability to reverse cholesterol transport(32), acting cytotoxicity(33) and exhibiting weaker ability to protect LDL and cell membranes from oxidation(34). The concept of dysfunctional HDL first arose from observations that some individuals with high or normal HDL-C but low PON1 activity were susceptible to Coronary Heart Disease (CHD) development, while others with low HDL-C but high PON1 activity were not(35).

It has been demonstrated that purified human PON1 can reduce the accumulation of lipid peroxides and substances reactive with thiobarbituric acid (TBARS, thiobarbituric acid reactive substances) in LDL molecules, during incubation of LDL with copper ions in vitro(36).

Anti-atherogenic activity of PON1, except from hydrolysis of oxidized phospholipids and cholesterol ester that are generated during oxidative modification of serum lipoproteins(13), include: enhancing cholesterol efflux from macrophages, restraining LDL oxidation induced by macrophages, restraining oxLDL uptake by macrophages(37).

It has been proven that macrophages isolated from mice with damaged PON1 gene have higher NADPH oxidase activity, have greater LDL oxidation capacity and lipid peroxide accumulation, and synthesize higher amounts of cholesterol when stimulated by oxidative stress than macrophages isolated from control mice(38). It was also confirmed that HDL lipoproteins isolated from transgenic mice overexpressing the PON1 gene, much more strongly stimulate the outflow of cholesterol from macrophages in the mechanism dependent on the ABCA1 protein carrier than HDL from mice with damaged PON1 gene(13).

Furthermore, in the in vitro study, purified PON1 inhibits, depending on the dose, the synthesis of cholesterol in isolated macrophages.(39)

In 2006, in vitro studies demonstrated a strong relationship between the antiatherogenic effects of PON1 and its ability to catalyze lactones. The weakening of the lactone function of PON1 reduces the ability of the enzyme to protect LDL from peroxidation, both in a cell-free system, i.e. induced by copper ions, and before oxidation stimulated by activated macrophages. PON1 lactonase activity also determines the ability of the enzyme to induce the outflow of cholesterol from macrophages(40).

Many data suggest that lipophilic lactones are the main natural substrates for PON1(41). Since many of the biologically active derivatives of fatty acids have a structure similar to lactones, it is suggested that the lipolactonase activity of PON1 can regulate the metabolism of these compounds and, as a result, modify the course of the inflammatory process and atherogenesis(42).

Anti-atherogenic effects of PON1 have also been confirmed in in vivo experiments. It has been shown that in apoE-damaged mice (apoE mice) in which severe atherosclerotic lesions develop in the vessels, additional damage to the PON1 gene enhances the development of these lesions(43). In contrast, the transfer of the human PON1 gene in apoE mice reduces the development of atheromatic changes(13).

Clinical trials also confirm the antiatherogenic effect of PON1. For example, a negative correlation was found between PON1 activity in plasma and the thickness of the IMT complex (intima media thickness)(44). It is generally believed that the value of the IMT complex in the carotid arteries correlates with the degree of atherosclerosis in the coronary arteries. The cardiovascular risk, mainly the incidence of heart attacks and strokes, increases with the thickness of the IMT complex(45). The inverse relationship between thiolactonase PON1 activity and IMT complex value was also proven(46). PON1 immunoreactivity was found in the wall of atherogenic-changed arteries(47) and it was proven that purified PON1 has the ability to hydrolyze lipid peroxides in homogenates prepared from atheromatic changes of the carotid and coronary arteries(48).

## **MODULATION OF PON1 ACTIVITY**

**GENETICS:** Both genetic and environmental factors can modify PON1 activity in plasma. Although many nutritional, life-style and pharmaceutical modulators of PON1 are known(49,50), the biggest effect on PON1 activity levels has PON1 genetic polymorphisms(21). Over 160 PON1 polymorphisms have been described, both in the coding region as well as in the introns or in the regulatory region of the gene. For example the coding region PON1-Q192R polymorphism determines a substrate dependent effect on activity. Some substrates e.g. paraoxon are hydrolysed faster by the R-isoform while others such as diazoxon are hydrolysed more rapidly by the Q-isoform(21). The PON1-Q192R polymorphism also determines the efficacy with which PON1 inhibits LDL oxidation with the Q isoform being the most efficient and the R isoform least efficient(10,51).

It is worth mentioning that the distribution of the PON1 polymorphisms varies with ethnicity. The frequency of the PON1-192R allele increases the further from Europe a population originates, the frequency in Caucasians of 15–30% increases to 70–90% in Far Eastern Oriental and Sub-Saharan African populations. These ethnic differences in Single Nucleotide Polimorphism (SNP) distribution can lead to large activity differences between populations(52).

**ENVIRONMENTAL FACTORS:** Although environmental factors do not influence PON1 activity as much as genetic polymorphisms, life-style, nutritional and pharmaceutical factors are still important PON1 modulators. Smoking has been shown to reduce plasma PON1 activity(53). Consumption of small amounts of alcohol in various forms increases the activity of PON1, while people who drink large amounts of alcohol have a reduced enzyme activity(54). A beneficial effect on PON1 activity is a diet rich in olive oil and in vitamins C and E(55), although some studies do not confirm the positive correlation between vitamin intake and PON1 activity in plasma(56). Polyphenolic flavonoids contained in red wine protect PON1 activity(57). Pomegranate juice rich in these antioxidants has a similar effect(58). Other dietary factors such as curcumin, betanin, isothiocyanates are also inducers of PON1, by mechanisms awaiting discovery(49,50,59). The lifestyle can also modulate PON1 activity, eg increase in physical activity increases PON1 activity(60).

### **PATHOLOGICAL FACTORS:**

Paraoxonase 1 is an antioxidant enzyme, however, under oxidative stress conditions, free oxygen radicals as well as oxidized phospholipids and cholesterol esters generated during the oxidation of lipoproteins and lysophosphatidylcholine may inactivate PON1(61). In vitro, a positive correlation was found between HDL oxidation and loss of PON1 hydrolytic activity and its ability to protect LDL against oxidation(62).

Currently, the increase in the level of nitrotyrosine in plasma is considered as a prognostic factor for the development of atherosclerotic lesions and the occurrence of cardiac events(63). Nitration of ApoA-I is also one of the mechanisms leading to the creation of the so-called dysfunctional, pro-atherogenic HDL(64). Nitration, like the oxidation of amino acid residues in apoA-I, causes conformational changes in the protein and weakens the binding and activity of enzymes transported by HDL molecules, including PON1 activity(65).

Incubation of HDL in a high concentration of glucose results in the accumulation of advanced glycation end products and substances reactive with thiobarbituric acid (TBARS) in HDL molecules and a decrease in PON1 activity against paraoxone(66). In diabetic patients there is an increase in the concentration of glycated LDL and HDL in the serum(67), which is dependent on the level of HbA1c(68). Moreover, a negative correlation was demonstrated between plasma PON1 activity and accumulation of advanced glycation end products in circulation(69). PON1 isolated from the plasma of patients with type 2 diabetes, is characterized by a higher glycation rate and decreased ability to mobilize lipid hydroperoxides from cell membranes in vitro(70).

Pro-inflammatory cytokines like IL-6, TNF-alpha, are responsible for the synthesis of acute-phase proteins including SAA. In the circulation, HDL is the main carrier of SAA. It has been proven that SAA can displace ApoA-I and PON1 from HDL molecules(71). Incubation of HDL with SAA may reduce the activity of PON1(72).

### **PHARMACOLOGICAL FACTORS:**

Due to its anti-atherosclerotic effects, PON1 is an interesting target for pharmacotherapy. In vitro studies have shown that HMG-CoA reductase inhibitors (3-hydroxy-3-methylglutaryl-CoA) - statins, such as pravastatin, simvastatin and fluvastatin, reduce the enzyme activity and reduce the expression of PON1 mRNA in hepatoma cells(73).

In rodents in vivo, fluvastatin and cerivastatin also inhibited plasma PON1 activity in rats with normal lipid profiles(74,75), and pravastatin did not affect PON1 activity in these animals(75). In clinical trials, atorvastatin(76) and fluvastatin(77), in addition to beneficial effects on the lipid profile, increased the activity of PON1.

Fibrates also have a varied effect on PON1 activity. The use of ciprofibrate for 3 months in patients with metabolic syndrome resulted in a decrease in triglycerides, an increase in HDL cholesterol and an increase in PON1 activity, as well as a significant reduction in serum oxLDL(78). In contrast, gemfibrozil and bezafibrate in patients with hyperlipidemia did not affect the enzyme activity(79). In rodents, fenofibrate reduced the activity of PON1 in normolipidemic rats(80). Similar results were obtained using gemfibrozil(81). On the other hand, in vitro fenofibrate increased the activity and expression of PON1 mRNA in human hepatocytes(73).

The beneficial effects on the activity and concentration of PON1 were corrected for aspirin(82).

Streptozocin-induced diabetic rats have been shown to have significantly reduced paraoxonase activity. Administration of metformin to streptozocin-induced diabetic rats for 4 weeks, significantly increases the hydrolytic activity of PON1, both for paraoxone and for phenyl acetate(83). On the other side, in streptozocin-induced diabetic rats as well as in

normal rats glimepiride and glibenclamide have no beneficial effects on circulating PON1 activity, but both drugs increase PON1 activity in the liver(84).

**CONCLUSION:** Clearly, it appears that serum PON1 contributes to the atheroprotective function of HDL by decreasing lipid peroxidation in a variety of diseases with an inflammatory component. Paraoxonase may be considered as a new therapeutic target while looking for new antiatherogenic drugs. Since complications of atherosclerosis like myocardial infarcts or strokes are the main cause of deaths in industrialized countries, more research in this field is definitely needed.

#### References:

1. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. *Am J Med.* 1977 May;62(5):707–14.
2. Tavori H, Khatib S, Aviram M, Vaya J. Characterization of the PON1 active site using modeling simulation, in relation to PON1 lactonase activity. *Bioorg Med Chem.* 2008 Aug 1;16(15):7504–9.
3. Mackness M, Mackness B. Human paraoxonase-1 (PON1): Gene structure and expression, promiscuous activities and multiple physiological roles. *Gene.* 2015 Aug 1;567(1):12–21.
4. Khersonsky O, Tawfik DS. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. *Biochemistry.* 2005 Apr 26;44(16):6371–82.
5. Aharoni A, Gaidukov L, Khersonsky O, McQ Gould S, Roodveldt C, Tawfik DS. The ‘evolvability’ of promiscuous protein functions. *Nat Genet.* 2005 Jan;37(1):73–6.
6. Draganov DI, Stetson PL, Watson CE, Billecke SS, La Du BN. Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. *J Biol Chem.* 2000 Oct 27;275(43):33435–42.
7. da Silva J, Moraes CR, Heuser VD, Andrade VM, Silva FR, Kvitko K, et al. Evaluation of genetic damage in a Brazilian population occupationally exposed to pesticides and its correlation with polymorphisms in metabolizing genes. *Mutagenesis.* 2008 Sep;23(5):415–22.
8. Lee BW, London L, Paulauskis J, Myers J, Christiani DC. Association between human paraoxonase gene polymorphism and chronic symptoms in pesticide-exposed workers. *J Occup Environ Med.* 2003 Feb;45(2):118–22.
9. Lacasaña M, López-Flores I, Rodríguez-Barranco M, Aguilar-Garduño C, Blanco-Muñoz J, Pérez-Méndez O, et al. Interaction between organophosphate pesticide exposure and PON1 activity on thyroid function. *Toxicol Appl Pharmacol.* 2010 Nov 15;249(1):16–24.
10. Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M, et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. *Arterioscler Thromb Vasc Biol.* 1998 Oct;18(10):1617–24.
11. Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. *J Biol Chem.* 2000 Feb 11;275(6):3957–62.
12. Jakubowski H. Homocysteine thiolactone: metabolic origin and protein homocysteinylation in humans. *J Nutr.* 2000;130(2S Suppl):377S-381S.

13. Aviram M, Rosenblat M. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. *Free Radic Biol Med.* 2004 Nov 1;37(9):1304–16.
14. Karabina S-AP, Lehner AN, Frank E, Parthasarathy S, Santanam N. Oxidative inactivation of paraoxonase--implications in diabetes mellitus and atherosclerosis. *Biochim Biophys Acta.* 2005 Sep 15;1725(2):213–21.
15. Harel M, Aharoni A, Gaidukov L, Brumshtein B, Khersonsky O, Meged R, et al. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. *Nat Struct Mol Biol.* 2004 May;11(5):412–9.
16. Khersonsky O, Tawfik DS. The histidine 115-histidine 134 dyad mediates the lactonase activity of mammalian serum paraoxonases. *J Biol Chem.* 2006 Mar 17;281(11):7649–56.
17. Yeung DT, Lenz DE, Cerasoli DM. Analysis of active-site amino-acid residues of human serum paraoxonase using competitive substrates. *FEBS J.* 2005 May;272(9):2225–30.
18. Sorenson RC, Primo-Parmo SL, Kuo CL, Adkins S, Lockridge O, La Du BN. Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase. *Proc Natl Acad Sci USA.* 1995 Aug 1;92(16):7187–91.
19. Blatter MC, James RW, Messmer S, Barja F, Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. *Eur J Biochem.* 1993 Feb 1;211(3):871–9.
20. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. *Science.* 1996 Jan 26;271(5248):518–20.
21. Deakin S, Leviev I, Gomaschi M, Calabresi L, Franceschini G, James RW. Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. *J Biol Chem.* 2002 Feb 8;277(6):4301–8.
22. Sorenson RC, Bisgaier CL, Aviram M, Hsu C, Billecke S, La Du BN. Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids : apolipoprotein A-I stabilizes activity. *Arterioscler Thromb Vasc Biol.* 1999 Sep;19(9):2214–25.
23. Mackness B, Durrington PN, Boulton AJM, Hine D, Mackness MI. Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls. *Eur J Clin Invest.* 2002 Apr;32(4):259–64.
24. Rosenblat M, Hayek T, Hussein K, Aviram M. Decreased macrophage paraoxonase 2 expression in patients with hypercholesterolemia is the result of their increased cellular cholesterol content: effect of atorvastatin therapy. *Arterioscler Thromb Vasc Biol.* 2004 Jan;24(1):175–80.
25. Ferretti G, Bacchetti T, Moroni C, Savino S, Liuzzi A, Balzola F, et al. Paraoxonase Activity in High-Density Lipoproteins: A Comparison between Healthy and Obese Females. *The Journal of Clinical Endocrinology & Metabolism.* 2005 Mar;90(3):1728–33.
26. Barbieri M, Bonafè M, Marfella R, Ragno E, Giugliano D, Franceschi C, et al. LL-paraoxonase genotype is associated with a more severe degree of homeostasis model assessment IR in healthy subjects. *J Clin Endocrinol Metab.* 2002 Jan;87(1):222–5.
27. McElveen J, Mackness MI, Colley CM, Peard T, Warner S, Walker CH. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. *Clin Chem.* 1986 Apr;32(4):671–3.

28. Ikeda Y, Suehiro T, Itahara T, Inui Y, Chikazawa H, Inoue M, et al. Human serum paraoxonase concentration predicts cardiovascular mortality in hemodialysis patients. *Clin Nephrol.* 2007 Jun;67(6):358–65.
29. Wójcicka G, Uniwersytet Medyczny (Lublin). Wpływ wybranych leków przeciwcukrzycowych na niektóre nietradycyjne czynniki ryzyka powikłań makronacyniowych w cukrzycy doświadczalnej u szczura. [Lublin]: Wydawnictwo Uniwersytetu Medycznego; 2012.
30. Aviram M. Review of human studies on oxidative damage and antioxidant protection related to cardiovascular diseases. *Free Radic Res.* 2000 Nov;33 Suppl:S85-97.
31. Ferretti G, Bacchetti T, Nègre-Salvayre A, Salvayre R, Dousset N, Curatola G. Structural modifications of HDL and functional consequences. *Atherosclerosis.* 2006 Jan;184(1):1–7.
32. Nicholls SJ, Zheng L, Hazen SL. Formation of dysfunctional high-density lipoprotein by myeloperoxidase. *Trends Cardiovasc Med.* 2005 Aug;15(6):212–9.
33. Alomar Y, Nègre-Salvayre A, Levade T, Valdiguié P, Salvayre R. Oxidized HDL are much less cytotoxic to lymphoblastoid cells than oxidized LDL. *Biochim Biophys Acta.* 1992 Oct 30;1128(2–3):163–6.
34. Ferretti G, Bacchetti T, Busni D, Rabini RA, Curatola G. Protective effect of paraoxonase activity in high-density lipoproteins against erythrocyte membranes peroxidation: a comparison between healthy subjects and type 1 diabetic patients. *J Clin Endocrinol Metab.* 2004 Jun;89(6):2957–62.
35. Navab M, Hama-Levy S, Van Lenten BJ, Fonarow GC, Cardinez CJ, Castellani LW, et al. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. *Journal of Clinical Investigation.* 1997 Apr 15;99(8):2005–19.
36. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. *FEBS Lett.* 1991 Jul 29;286(1–2):152–4.
37. Tavori H, Vaya J, Aviram M. Paraoxonase 1 Attenuates Human Plaque Atherogenicity: Relevance to the Enzyme Lactonase Activity. In: Reddy ST, editor. *Paraoxonases in Inflammation, Infection, and Toxicology* [Internet]. Totowa, NJ: Humana Press; 2010 [cited 2019 Jan 8]. p. 99–111. Available from: [http://link.springer.com/10.1007/978-1-60761-350-3\\_10](http://link.springer.com/10.1007/978-1-60761-350-3_10)
38. Rozenberg O, Rosenblat M, Coleman R, Shih DM, Aviram M. Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. *Free Radic Biol Med.* 2003 Mar 15;34(6):774–84.
39. Rozenberg O, Shih DM, Aviram M. Human serum paraoxonase 1 decreases macrophage cholesterol biosynthesis: possible role for its phospholipase-A2-like activity and lysophosphatidylcholine formation. *Arterioscler Thromb Vasc Biol.* 2003 Mar 1;23(3):461–7.
40. Rosenblat M, Gaidukov L, Khersonsky O, Vaya J, Oren R, Tawfik DS, et al. The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. *J Biol Chem.* 2006 Mar 17;281(11):7657–65.
41. Gaidukov L, Tawfik DS. The development of human sera tests for HDL-bound serum PON1 and its lipolactonase activity. *J Lipid Res.* 2007 Jul;48(7):1637–46.
42. Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. *J Lipid Res.* 2005 Jun;46(6):1239–47.
43. Shih DM, Xia YR, Wang XP, Miller E, Castellani LW, Subbanagounder G, et al. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit



- increased lipoprotein oxidation and atherosclerosis. *J Biol Chem.* 2000 Jun 9;275(23):17527–35.
44. Harangi M, Seres I, Magyar MT, Csipo I, Sipka S, Valikovics A, et al. Association between Human Paraonase 1 Activity and Intima-Media Thickness in Subjects under 55 Years of Age with Carotid Artery Disease. *Cerebrovascular Diseases.* 2008;25(1–2):122–8.
  45. Ogata T, Yasaka M, Yamagishi M, Seguchi O, Nagatsuka K, Minematsu K. Atherosclerosis found on carotid ultrasonography is associated with atherosclerosis on coronary intravascular ultrasonography. *J Ultrasound Med.* 2005 Apr;24(4):469–74.
  46. Kosaka T, Yamaguchi M, Motomura T, Mizuno K. Investigation of the relationship between atherosclerosis and paraonase or homocysteine thiolactonase activity in patients with type 2 diabetes mellitus using a commercially available assay. *Clin Chim Acta.* 2005 Sep;359(1–2):156–62.
  47. Mackness B, Hunt R, Durrington PN, Mackness MI. Increased immunolocalization of paraonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. *Arterioscler Thromb Vasc Biol.* 1997 Jul;17(7):1233–8.
  48. Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffman A, et al. Human serum paraonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. *Circulation.* 2000 May 30;101(21):2510–7.
  49. Costa LG, Vitalone A, Cole TB, Furlong CE. Modulation of paraonase (PON1) activity. *Biochem Pharmacol.* 2005 Feb 15;69(4):541–50.
  50. Schrader C, Rimbach G. Determinants of paraonase 1 status: genes, drugs and nutrition. *Curr Med Chem.* 2011;18(36):5624–43.
  51. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the human serum paraonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. *FEBS Lett.* 1998 Feb 13;423(1):57–60.
  52. La Du BN, Adkins S, Kuo C-L, Lipsig D. Studies on human serum paraonase/arylesterase. *Chemico-Biological Interactions.* 1993 Jun;87(1–3):25–34.
  53. Nishio E, Watanabe Y. Cigarette smoke extract inhibits plasma paraonase activity by modification of the enzyme's free thiols. *Biochem Biophys Res Commun.* 1997 Jul 18;236(2):289–93.
  54. Rao MN, Marmillot P, Gong M, Palmer DA, Seeff LB, Strader DB, et al. Light, but not heavy alcohol drinking, stimulates paraonase by upregulating liver mRNA in rats and humans. *Metab Clin Exp.* 2003 Oct;52(10):1287–94.
  55. Wallace AJ, Sutherland WH, Mann JI, Williams SM. The effect of meals rich in thermally stressed olive and safflower oils on postprandial serum paraonase activity in patients with diabetes. *Eur J Clin Nutr.* 2001 Nov;55(11):951–8.
  56. Ferré N, Camps J, Fernández-Ballart J, Arija V, Murphy MM, Ceruelo S, et al. Regulation of serum paraonase activity by genetic, nutritional, and lifestyle factors in the general population. *Clin Chem.* 2003 Sep;49(9):1491–7.
  57. Hayek T, Fuhrman B, Vaya J, Rosenblat M, Belinky P, Coleman R, et al. Reduced progression of atherosclerosis in apolipoprotein E-deficient mice following consumption of red wine, or its polyphenols quercetin or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation. *Arterioscler Thromb Vasc Biol.* 1997 Nov;17(11):2744–52.
  58. Kaplan M, Hayek T, Raz A, Coleman R, Dornfeld L, Vaya J, et al. Pomegranate juice supplementation to atherosclerotic mice reduces macrophage lipid peroxidation, cellular

- cholesterol accumulation and development of atherosclerosis. *J Nutr.* 2001 Aug;131(8):2082–9.
59. Deakin SP, James RW. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. *Clin Sci.* 2004 Nov;107(5):435–47.
  60. Senti M, Tomás M, Anglada R, Elosua R, Marrugat J, Covas MI, et al. Interrelationship of smoking, paraoxonase activity, and leisure time physical activity: a population-based study. *Eur J Intern Med.* 2003 May;14(3):178–84.
  61. Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, et al. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. *Free Radic Biol Med.* 1999 Apr;26(7–8):892–904.
  62. Jaouad L, Milochevitch C, Khalil A. PON1 paraoxonase activity is reduced during HDL oxidation and is an indicator of HDL antioxidant capacity. *Free Radic Res.* 2003 Jan;37(1):77–83.
  63. Hermo R, Mier C, Mazzotta M, Tsuji M, Kimura S, Gugliucci A. Circulating levels of nitrated apolipoprotein A-I are increased in type 2 diabetic patients. *Clin Chem Lab Med.* 2005;43(6):601–6.
  64. Shao B, Bergt C, Fu X, Green P, Voss JC, Oda MN, et al. Tyrosine 192 in apolipoprotein A-I is the major site of nitration and chlorination by myeloperoxidase, but only chlorination markedly impairs ABCA1-dependent cholesterol transport. *J Biol Chem.* 2005 Feb 18;280(7):5983–93.
  65. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. *Pharmacol Rev.* 2006 Sep;58(3):342–74.
  66. Hedrick CC, Thorpe SR, Fu MX, Harper CM, Yoo J, Kim SM, et al. Glycation impairs high-density lipoprotein function. *Diabetologia.* 2000 Mar;43(3):312–20.
  67. Numano F, Tanaka A, Makita T, Kishi Y. Glycated lipoprotein and atherosclerosis. *Ann N Y Acad Sci.* 1997 Apr 15;811:100–13; discussion 113–114.
  68. Jenkins AJ, Rowley KG, Lyons TJ, Best JD, Hill MA, Klein RL. Lipoproteins and diabetic microvascular complications. *Curr Pharm Des.* 2004;10(27):3395–418.
  69. Zhou H, Tan KCB, Shiu SWM, Wong Y. Increased serum advanced glycation end products are associated with impairment in HDL antioxidative capacity in diabetic nephropathy. *Nephrol Dial Transplant.* 2008 Mar;23(3):927–33.
  70. Mastorikou M, Mackness B, Liu Y, Mackness M. Glycation of paraoxonase-1 inhibits its activity and impairs the ability of high-density lipoprotein to metabolize membrane lipid hydroperoxides. *Diabet Med.* 2008 Sep;25(9):1049–55.
  71. Van Lenten BJ, Wagner AC, Nayak DP, Hama S, Navab M, Fogelman AM. High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection. *Circulation.* 2001 May 8;103(18):2283–8.
  72. Cabana VG, Reardon CA, Feng N, Neath S, Lukens J, Getz GS. Serum paraoxonase: effect of the apolipoprotein composition of HDL and the acute phase response. *J Lipid Res.* 2003 Apr;44(4):780–92.
  73. Gouédard C, Koum-Besson N, Barouki R, Morel Y. Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. *Mol Pharmacol.* 2003 Apr;63(4):945–56.
  74. Bełtowski J, Wójcicka G, Mydlarczyk M, Jamroz A. Cerivastatin modulates plasma paraoxonase/arylesterase activity and oxidant-antioxidant balance in the rat. *Pol J Pharmacol.* 2002 Apr;54(2):143–50.

75. Bełtowski J, Wójcicka G, Jamroz A. Differential effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on plasma paraoxonase 1 activity in the rat. *Pol J Pharmacol.* 2002 Dec;54(6):661–71.
76. Harangi M, Seres I, Varga Z, Emri G, Szilvássy Z, Paragh G, et al. Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage. *Eur J Clin Pharmacol.* 2004 Dec;60(10):685–91.
77. Mirdamadi HZ, Sztanek F, Derdak Z, Seres I, Harangi M, Paragh G. The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters. *Br J Clin Pharmacol.* 2008 Sep;66(3):366–74.
78. Paragh G, Seres I, Harangi M, Erdei A, Audikovszky M, Debreczeni L, et al. Ciprofibrate increases paraoxonase activity in patients with metabolic syndrome. *Br J Clin Pharmacol.* 2006 Jun;61(6):694–701.
79. Durrington PN, Mackness MI, Bhatnagar D, Julier K, Prais H, Arrol S, et al. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. *Atherosclerosis.* 1998 May;138(1):217–25.
80. Bełtowski J, Wójcicka G, Mydlarczyk M, Jamroz A. The effect of peroxisome proliferator-activated receptors alpha (PPARalpha) agonist, fenofibrate, on lipid peroxidation, total antioxidant capacity, and plasma paraoxonase 1 (PON 1) activity. *J Physiol Pharmacol.* 2002 Sep;53(3):463–75.
81. Macan M, Marija M, Konjevoda P, Paško K, Lovric J, Jasna L, et al. The influence of gemfibrozil on malondialdehyde level and paraoxonase 1 activity in wistar and fisher rats. *Basic Clin Pharmacol Toxicol.* 2011 Jun;108(6):428–35.
82. Blatter-Garin MC, Kalix B, De Pree S, James RW. Aspirin use is associated with higher serum concentrations of the anti-oxidant enzyme, paraoxonase-1. *Diabetologia.* 2003 Apr;46(4):593–4.
83. Wójcicka G, Jamroz-Wiśniewska A, Czechowska G, Korolczuk A, Marciniak S, Bełtowski J. The paraoxonase 1 (PON1), platelet-activating factor acetylhydrolase (PAF-AH) and dimethylarginine dimethylaminohydrolase (DDAH) activity in the metformin treated normal and diabetic rats. *Eur J Pharmacol.* 2016 Oct 15;789:187–94.
84. Wójcicka G, Jamroz-Wiśniewska A, Marciniak A, Łowicka E, Bełtowski J. The differentiating effect of glimepiride and glibenclamide on paraoxonase 1 and platelet-activating factor acetylhydrolase activity. *Life Sci.* 2010 Jul 17;87(3–4):126–32.